

Impact of *Demodex* Blepharitis on Patients and the Healthcare System: Results from the Atlas Continuation Study

Presented at ARVO 2022

Authors

Blake Simmons, OD; Patrick Vollmer, OD; William Whitson, MD; Gregg Berdy, MD; Mark Holdbrook; Stephanie Baba, OD; John Meyer, MD

PURPOSE

- 1** Further evaluate the clinical impact of *Demodex* blepharitis
- 2** Infer patient quality of life (QoL) impact
- 3** Understand patient motivations of seeking care

METHODOLOGY



Subject Demographic

- ≥ 18 years old (mean age 66±14)



524 patients



Study Design

Prospective, observational study
Clinical measurements signifying *Demodex* blepharitis

- ≥ 1.0 mite per lash
- > 10 collarettes (cylindrical dandruff) on the lashes
- ≥ mild lid margin erythema

Questionnaire on patients' QoL and *Demodex* blepharitis experience




Study Site(s)

- 20 US eye care centers


FINDINGS

See the graphs below that highlight *Demodex* blepharitis patients' symptoms, motivation to seek care, and impact on daily life.


Most patients with *Demodex* blepharitis made multiple doctor visits and went for years without a proper diagnosis




Blurred/foggy vision and discomfort negatively affected contact lens wearers with *Demodex* blepharitis




Itchy eyes and dry eyes were the most commonly reported patient symptoms of *Demodex* blepharitis



Demodex blepharitis negatively impacted patients



Options to mitigate *Demodex* blepharitis showed high discontinuation due to ineffectiveness or intolerability



CONCLUSION



Proper *Demodex* blepharitis diagnosis with an FDA-approved treatment that is **safe, tolerable, and effective** is needed for eyecare patients to address and improve their symptoms and quality of life.

46%

Of patients who discontinued their regimen, discontinued due to ineffectiveness or tolerability issues